Pinealon

Third-Party Tested

Independent lab verified

Batch-Specific CoA

Publicly accessible

YPB.273

Reference number

20mg

Lyophilized vial

Origin

Pinealon (Glu-Asp-Arg) is a synthetic tripeptide developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology. It belongs to the class of short regulatory peptides (bioregulators) that Khavinson's group has systematically developed based on tissue-specific peptide fragments identified in organ extracts.

Research Lineage

Khavinson's research program has identified numerous tissue-specific short peptides, with Pinealon characterized as brain-specific. Studies by Khavinson, Linkova, and colleagues have investigated its effects on brain cortex cell cultures under conditions of oxidative stress and hypoxia. The compound is part of the broader Russian bioregulation research tradition.

Mechanism of Action

Pinealon has been observed to penetrate cell membranes and interact with DNA, potentially influencing gene expression related to neuroprotection. In cell culture studies, it has been investigated for effects on serotonin and melatonin synthesis pathways. Khavinson's group proposes that short peptides act as epigenetic regulators by binding to specific DNA sequences in gene promoter regions.

Structural Notes

Tripeptide. Sequence: Glu-Asp-Arg. Molecular weight: 404.37 Da.